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Abstract
Background:  We would expect information on adverse drug reactions in randomised clinical
trials to be easily retrievable from specific searches of electronic databases. However, complete
retrieval of such information may not be straightforward, for two reasons. First, not all clinical drug
trials provide data on the frequency of adverse effects. Secondly, not all electronic records of trials
include terms in the abstract or indexing fields that enable us to select those with adverse effects
data. We have determined how often automated search methods, using indexing terms and/or
textwords in the title or abstract, would fail to retrieve trials with adverse effects data.
Methods:  We used a sample set of 107 trials known to report frequencies of adverse drug effects,
and measured the proportion that (i) were not assigned the appropriate adverse effects indexing
terms in the electronic databases, and (ii) did not contain identifiable adverse effects textwords in
the title or abstract.
Results:  Of the 81 trials with records on both MEDLINE and EMBASE, 25 were not indexed for
adverse effects in either database. Twenty-six trials were indexed in one database but not the
other. Only 66 of the 107 trials reporting adverse effects data mentioned this in the abstract or
title of the paper. Simultaneous use of textword and indexing terms retrieved only 82/107 (77%)
papers.
Conclusions:  Specific search strategies based on adverse effects textwords and indexing terms
will fail to identify nearly a quarter of trials that report on the rate of drug adverse effects.
Background
Both physicians and patients need to know the likelihood
of adverse effects of drugs in order to assess the effica-
cy:risk ratio of a particular therapy. This applies to seri-
ous clinical effects that may cause significant morbidity
or mortality, and to more "trivial" symptoms that may af-
fect quality of life and drug compliance. Lists of adverse
effects can be obtained from reference texts or pharma-
ceutical companies, but details of frequencies are often
not available [1]. Randomised controlled trials, in con-
junction with case reports and observational studies, can
potentially provide useful evidence on the frequencies of
adverse effects. However, some trials are too small for re-
liable estimates, making a systematic review of the data
– ideally a meta-analysis – necessary, and in order to
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carry out an unbiased review, we need to retrieve a com-
plete set of data.
We became aware, from our own meta-analytical work
[2], that apparently comprehensive search strategies
combining textwords (e.g. "drug name" and "adverse or
side effect" and "trial") with indexing terms (e.g. "drug-
AE" and "clinical trial") may not always succeed in re-
trieving records that we know to exist from hand search-
es. We therefore set out to determine the number of
instances in which automated searches of the EMBASE
and MEDLINE databases would fail to retrieve trials that
we already knew contained adverse effects data.
Methods
We used a sample of papers culled from review articles in
which the adverse effects of drug therapy were part of the
analysis [2–5]. We manually selected papers that were
known to have reported data on the frequency of adverse
effects and checked to see if:
1. they had been indexed with the relevant terms for ad-
verse effects, using the Silver Platter Information Re-
trieval System to check the indexing of their records on
the MEDLINE and EMBASE electronic databases;
2. the authors mentioned adverse effects (or any related
terms) in the title or abstract (thus enabling the paper to
be found in an electronic search).
The absence of both features would make the search pro-
cedure far more difficult and time-consuming for those
interested in identifying and retrieving papers that re-
ported adverse effects data.
Details of the papers included in the review
Our sample consisted of reports of randomised control-
led trials that had been retrieved through a combination
of electronic searching and manual checking of full-text
articles. All the papers (for a full list see  [http://
www.clinpharm.ox.ac.uk/AEsearch/reflist.htm] ) re-
ported the presence or absence of adverse effects and
provided figures for the rates of adverse effects in both
the treated and control arms.
The papers we surveyed came from review articles as-
sessing:
1. the risk of gastrointestinal haemorrhage with aspirin –
37 papers reporting on 24 trials [2];
2. the risk of adverse effects with antihypertensive agents
– 13 papers reporting on 13 trials [3];
3. the adverse effects of analgesics in postoperative pain
– 28 papers on paracetamol (acetaminophen) and 29 on
ibuprofen [4,5].
The aspirin review specifically studied gastrointestinal
bleeding, so the free text terms "h(a)emorrhage",
"bleed(ing)", "mel(a)ena", "h(a)ematemesis", and "gas-
trotoxic" were accepted as relevant, in addition to gener-
al terms such as "side/adverse effect". The other two
reviews studied all adverse effects associated with the
drugs. Since a potential reviewer would not know in ad-
vance of a search all the observed/reported adverse ef-
fects, we looked in the title and abstract for general terms
such as "side/adverse effect" (which might be used to
qualify specific symptoms, such as nausea), and accepted
specific symptoms in the indexing fields only when they
were clearly categorized as adverse effects, e.g. "nausea-
CI" or "nausea-SE".
All the papers were indexed on either MEDLINE (n =
100), or EMBASE (n = 88), or both (n = 81). However, in
seven papers the abstract was missing from the electron-
ic database, and in those cases our findings are based on
the textwords present in the abstracts of the printed ver-
sions.
Results
Papers that reported adverse effects were not consistent-
ly indexed in the two electronic databases (Figure 1). Of
the 81 records logged in both MEDLINE and EMBASE,
only 30 (37%) were indexed for adverse effects in both
databases. In most instances, papers were indexed in one
but not the other (26/81), or were not indexed in either
(25/81). When each database was assessed individually,
there was little difference in the proportion of papers in-
dexed for adverse effects – MEDLINE 53/100 records
(53%) and EMBASE 43/88 records (49%) – although, as
is clear from Figure 1, they each indexed different sets of
papers.
Similarly, a large proportion of papers did not mention
adverse effects (or related terms) in the title or abstract,
and therefore would not have been detected using a tex-
tword search (Table 1). A combined search covering the
two databases and using both the index and textword
terms would still have failed to pick up 25 of the 107 pa-
pers that contained adverse effects data.
Full details of the textwords and indexing terms for ad-
verse effects used in the papers can be found in Table 2,
Table 3 and Table 4.BMC Medical Research Methodology 2001, 1:7 http://www.biomedcentral.com/1471-2288/1/7
Figure 1
Assignment of indexing terms for adverse effects in 81 papers with records available in both Medline and EMBASE. All the
papers were known to contain information on adverse effects.BMC Medical Research Methodology 2001, 1:7 http://www.biomedcentral.com/1471-2288/1/7
Discussion
Our results show that automated searches of MEDLINE
and EMBASE will not succeed in retrieving all trials with
adverse effects data because:
• indexing terms for adverse effects were not assigned to
some of the papers, even though they contained data on
adverse effects frequencies;
• the authors made no mention of adverse effects (or re-
lated terms) in the title or abstract, although the paper it-
self contained numerical information about adverse
effects.
This latter point explains the failure of textword search-
es; more importantly, it shows that manual checking of
trial abstracts will not help reviewers in determining
whether adverse effects data are available from a trial re-
port.
There are several reasons for this failure to mention ad-
verse effects in abstracts of papers or indexes of databas-
es. Guidelines on the structured reporting of clinical
trials are directed towards the reporting of therapeutic
efficacy [6]. Authors may not feel that adverse effects de-
serve a mention in the confined space of an abstract, es-
pecially as there are already so many other requirements
about the information they need to provide.
There are no specific rules concerning what merits in-
dexing as "drug toxicity" or "side effect" in the EMBASE
database, but general guidelines are that indexing should
take place if significant information relevant to clinical
use is presented in the article (Jos Hageman, personal
communication). Indexing terms for adverse effects in
the MEDLINE database are generally assigned only to
papers in which the author devotes substantive discus-
sion to the adverse effects (Ione Auston, Beth Van Lent-
en, personal communication). This usually occurs only
when the author considers the effects to be significant or
serious. However, most trials are not powered to detect
significant differences in rates of adverse effects, and se-
rious ones tend to be rare. Furthermore, few authors ac-
tually devote substantial amounts of space to safety data
[7]. This may explain why only about half of the trials we
surveyed in which adverse effects data were reported had
been assigned adverse effects indexing terms.
Data on adverse effects could be more easily retrieved if
trials that reported adverse effects were distinguishable
Table 1: Number of papers that could be retrieved based on the reporting of adverse effects.
Drug (total number of papers) Aspirin (37) Antihypertensive drugs 
(13)
Ibuprofen (29) Paracetamol (28)
Adverse effects textwords present 18 (49%) 8 (62%) 20 (69%) 16 (57%)
Indexed in either Medline or EMBASE 28 (76%) 8 (62%) 18 (62%) 15 (54%)
Retrievable by a combined search 29 (78%) 9 (69%) 24 (83%) 20 (71%)
*Abstract from seven of the 107 papers were missing from the electronic databases; in these cases, the printed abstracts were analysed.
Table 2: "Adverse Effects" Textwords in Titles or Abstracts*
Drug AE term as Terms used
(no. of papers) textword* [frequency]
Aspirin
(37)
18 bleed(s/ing) [11], side effects [5], haemorrhag(e/ic) [4], adverse effects [3], safe(ty) [2], adverse event [1], 
gastrotoxic [1], haematemesis [1], melaena [1]
Antihypertensive drugs 8 adverse effects [3], side effects [3], adverse reactions [1], risks [1]
(13)
Ibuprofen
(29)
20 tolerability/tolerance/well tolerated [9], adverse effects [8], safe(ty) [6], side effect(s) [5], adverse events 
[2], unwanted effects
Paracetamol
(28)
16 side effects [7], adverse effects [5], tolerability/tolerance/well tolerated [4], safe(r/ty) [3], adverse reac-
tions [2], adverse events [1]
*Abstracts from seven of the 107 papers were missing from the electronic databases; in these cases, the printed abstracts were analysed.BMC Medical Research Methodology 2001, 1:7 http://www.biomedcentral.com/1471-2288/1/7
in electronic databases from those that did not. However,
about 23% of papers containing adverse effects data do
not have any adverse effects textwords or indexing terms
attached to them, and would therefore be missed by elec-
tronic searches. These papers can be identified only by
using a broad search strategy with no specific adverse ef-
fects terms, followed by manual (and potentially labori-
ous) searching of the full-text versions. We found this to
be true whether we were searching for a specific adverse
Table 3: Indexing for Adverse Effects in MEDLINE
Drug Records Indexed Terms used
avaliable for AE [frequency]
Aspirin 37 26 Aspirin-AE [25]
Hemorrhage-CI [5]
Platelet-aggregating-inhibitor-AE [3]
Safety [1]
Antihypertensives 13 6 Antihypertensive agents-AE [5]
Named drug*-AE [2]
Ibuprofen 23 12 Ibuprofen-AE [12] Antiinflammatory-agent-non-steroidal-AE [2]
Analgesics-AE [1]
Paracetamol 27 9 Acetaminophen-AE [9]
*name of any antihypertensive drug (e.g. atenolol, enalapril, nifedipine)
Table 4: Indexing for Adverse Effects in EMBASE
Drug Records Indexed Terms used
(no. of reports) available for AE [frequency]
Aspirin 30 16 Adverse-reactions-titles [13]
(37) Bleeding-SE [8]
GI-hemorrhage-SE [5]
Adverse-drug-reaction [4]
Antithrombotic-agent-ADR [2]
ASA-ADR [10], ASA-SE [1]
Hematemesis-SE [1], Melena-SE [1]
Stomach-hemorrhage-SE [1]
Antihypertensive drugs 9 3 Adverse-drug-reaction [3]
(13) Adverse-reactions-titles [1]
Ibuprofen 26 13 Adverse-reactions-titles [12]
(29) Specific symptom*-SE [9]
Ibuprofen-ADR [8]
Adverse-drug-reaction [3]
Analgesic-agent-ADR [1]
Drug-safety [1]
Drug-tolerability [1]
Nonsteroidal-antiinflammatory-agent-AE [1]
Side effect [1]
Paracetamol 23 11 Adverse-drug-reactions-titles [10]
(32) Adverse-drug-reaction [8]
Paracetamol-ADR [2]
Specific symptom*-SE   [2]
Drug-safety [1]
*any named symptom (e.g. nausea, vomiting)BMC Medical Research Methodology 2001, 1:7 http://www.biomedcentral.com/1471-2288/1/7
effect associated with a specific drug, or for all adverse
effects associated with a specific drug or type of therapy.
It is important that search strategies should reliably re-
trieve all trials in which drug adverse effects are report-
ed, so that we can readily access and use all the existing
evidence. However, index-based searches for adverse ef-
fects may omit papers that do not report significant or se-
rious adverse effects. Unreliable estimates of the rate or
severity of drug adverse effects may occur as a result of
these limitations in the current indexing system.
Although there has been some recent interest in improv-
ing the adequacy of adverse effects reporting in clinical
trials [6,7] the benefits of better reporting may be wasted
if steps are not taken to make the data more easily avail-
able. A number of relatively simple changes to both the
reporting and indexing of drug adverse effects could sig-
nificantly increase the accessibility of such evidence from
future publications, and allow more reliable estimates of
their significance to be given to patients. As such, we
make the following proposals:
1. Indexers should agree on a unified system for indexing
drug adverse effects. Any trial that reports on the fre-
quency of adverse effects needs to be indexed, even if the
adverse effects were judged not significant or not severe.
Information on the absence of serious adverse effects is
of no less value to those who are involved in making ther-
apeutic decisions.
2. Journals that publish structured abstracts should re-
quire authors to mention drug adverse effects in the ab-
stract whenever they are reported in randomised
controlled trials, even if no adverse drug reactions oc-
curred in the trial.
Conclusions
Implications for clinical practice
Clinical staff using quick and specific search methods for
trial data on adverse effects will fail to retrieve some po-
tentially relevant papers, and may retrieve a biased selec-
tion.
Implications for research
Researchers carrying out systematic reviews of adverse
drug effects in clinical trials will need to carry out manual
checking of full-text articles of all trials of the relevant
drug in order to ascertain whether adverse effects data
are reported or not.
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